Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It does sound like good news!
I do expect to see an ENZC PR on it. The information we have is currently vague ("large batch" sometime "next year" delivered "to Africa") and forward looking statements from Rosetta Lifecare Bulgaria aren't regulated like ENZC's statements would be. (It's also brand new information, so surely we'll get more details in the coming days.)
Very nice!!
I think the OTC is a different animal now. Things boomed earlier this year on the tail of a stronger economy, kind of like the parabolic spike you'd see right before a run ends and there's sudden pullback. My mainstream friends were 'getting into investing' with their stimulus checks which is a bad sign that everybody's on a bandwagon - that type of frenzy is unsustainable in the long term.
Saw it with crypto too right before that pulled way back!
I'm under the impression the OTC is mostly traded with computer algorithms now. The market movers can draw whatever they want for a chart, and their software will adapt day-to-day to make it happen. Stuff is allowed to run temporarily to keep retail pouring in new money. The important takeaway is that regardless of pumps, everything is currently in steady downtrend.
Eventually MMs will need to let stuff run to continue making money, but imo they're nowhere near draining all the retail that's hanging on for better days, and people are still falling for the dead cat bounces and reddit pumps.
$ENZC is one of a few OTC companies in its space that actually has solid DD and a bright future ahead. And even it can't keep its head above water just with patents and promises. I'm in another OTC bio ticker that was up 6% today, but only because that company has an actual breakthrough drug on the market to accompany their patents and promises - that's the kind of clout ENZC and its peers need to build to overcome this market's downward pressure.
Re: a market crash? Increasingly, retail is selling out to be able to afford skyrocketing inflation in the fall and winter months. The government's policies seem to be anti-capitalism and anti-private-sector. Crashes happen when too many investors feel deeply bearish, get triggered by a catalyst (which might even just be other bears selling into a red candle), and rush to take whatever they can get for their shares. Personally I'm seeing waning optimism in most tickers, and flippers everywhere. Further bearish catalysts when the market is this depressed could cause quite a dent!
Good DD!
Chandra said there would be "exponential growth" (source) and that we've only seen the "tip of the iceberg" (source). If he's being honest and making a fair evaluation, things could start falling into place quickly.
I sold a bunch Monday to mitigate risk, but I'm not selling all. Too much potential in the pipeline for 2022.
Good point and I agree, it almost reads like they didn't get the numbers from partners by the deadline. There may also be an agreement that while ENZC gets its share of revenue, that revenue isn't delivered until months (quarters?) after it's earned, to give the other company time for accounting.
I'm still surprised to see zero revenue reported after some was already reported last quarter and we know there's been a product on the market (the partners' product) with a revenue-sharing deal in place. If Harry is sharing royalties from ITV-1 licensing with ENZC, then we should at least see a number from ongoing Bulgarian/EU sales of EnzoImmune Active unless I'm overlooking something key.
Hence the disclaimer!
"Skip the charting if you don't wanna see charts" :P
Great post, thanks!
Quick charting/analysis for Tuesday,
(Skip the charting if you don't wanna see charts. Curious to hear your take as well!)
I hope the market still thinks the levels around .12 are a bargain price! The engulfing bear candle Monday could be from investors panicking at the possibility ENZC wouldn't post their financials in time to avoid a yield sign. In that case, hopefully the market already factored in the losses and there's a rebound coming Tuesday.
But the financials weren't exciting at all, and raised new questions including the F series shares and lack of expected quarterly revenue. Additionally, with ITV-1 production for clinical trials now delayed until 2022 due to defective lab equipment, do we know of any catalyst that would keep people excited enough to buy at current levels vs waiting for more action and a better price?
Looking at the chart, price finally closed below the projected support line for the first time ever in this price range. That line has reflected the bears half a dozen or more times, so seeing price reach the secondary projection in an engulfing red candle is concerning. The overall structure since 4/16 (the whole chart here) resembles a Head & Shoulders reversal pattern. RSI has plenty of room to diminish further and MACD also crossed into red ticks. The saving grace is low volume, but higher volume could happen as a selloff and not a reversal if investors start to move en masse.
These signals taken together, Tuesday could be brutal if bulls don't rally.
If Tuesday's decisively red, I'm expecting a new downtrend that will eventually take price to around .09 to form a double bottom with the lows in April. Fibonacci short targets include .114 and .066 as other possibilities. Bulls pumping new cash into this Tuesday could go far to stave off the worst outcomes!
GLTA
Yeah that part about needing an extension to write zeros for 'international business expansion' looks a bit shady!
I looked carefully through the numbers in the current quarterly and compared to the prior. Didn't see anything glaring, though the numbers don't seem to show international business expansion (or even any unusual activity) and there are a couple weird spots.
https://www.otcmarkets.com/otcapi/company/financial-report/297979/content
https://www.otcmarkets.com/otcapi/company/financial-report/312797/content
First a quick breakdown:
Comparing assets in the Balance Sheets on page 1, the numbers are exactly the same for "Other Assets". The numbers are also exactly the same for "Current Assets" except "Cash and cash equivalents" dropped about $395k, and "Property and equipment, net" increased about $13k. No money coming in.
Comparing Statements of Operations from the second page, the numbers for Q3 are similar to Q2 except for three notable differences in the Q3 financials:
- There were zero License Revenues
- There were zero Research and Development expenses
- General and administrative category increased about $43k
In the latest quarterly, in "(9) Subsequent Events" on the very last page:
Isn't that exactly the same reason they gave last time? But I'm glad they got them filed this time to stay pink current. :)
That's really interesting about STXG... if they have shares to sell but never bought any, they would have to be acting on behalf of a party with shares, yes? Maybe an insider who needs some spending money.
I agree with a reply that the company itself wouldn't be diluting, otherwise it would seem there'd be more price manipulation first.
Another possibility is naked shorting, which is illegal but especially probable in this year's OTC. If STXG is banking on other MMs driving the price down, they might short shares out of thin air and cover lower for some quick profits at the bottom.
This doesn't look like dilution to me, and it doesn't look like longs are unloading either. I can show it if you don't mind looking at charts:
Look at Accumulation Distribution (AccDist) and OnBalanceVolume (OBV) in the chart below. Both lines are in positive territory, trended up and have held pretty steady.
Contrast this to charts (from last month) from a company with strong dilution: every time PS*U runs, it gets much more distributed, and AccDist gets much more negative, with OBV squiggly as well. https://i.ibb.co/j4hvL7y/20211007-psru-accdist.png
ENZC has been losing a lot of value on relatively low volume. The losses should be erased quickly whenever serious buy volume comes back in. Serious buy volume won't happen until the company delivers something significant, so everybody's stuck in the waiting game until then.
Price is currently testing a critical support level. Not pretty to watch, but support is holding so far.
WARNING: This post contains charts. Skip it if you don't believe the OTC can be charted.
(You'd think I wouldn't need the disclaimer, haha.)
On the daily chart, there's a support level projected from the low in April. It has acted as support at every opportunity since then. Today's action drove price about as low as possible without closing under that top line.
If support holds tomorrow, I would expect price to fall as low as .117 to touch the secondary line before rebounding -- but whatever happens I'd like to see the daily candle close above that upper support line to avoid signaling a major & bearish pattern change.
Other TA I do shows mixed bearish/bullish signals, so from a TA perspective it's kind of a toss up what this is gonna do. I'm not at all comfortable with the shape of the structure that's formed in the candles since April. It's similar to a Head & Shoulders reversal pattern which could suggest an imminent sharp continuation of this year's downtrend. The market rejected .30 and .20 in series, and it's currently deciding whether to reject levels around .10
IMO the most likely explanation for today's price action is the one from MAGA_PATRIOT: we are 4 days away from a Short Interest Settlement Date, so MM's are likely shaking the tree to get the best price for covering their shorts. Why is this likely? Because we've seen it many times already. In this scenario, support should indeed hold, and we would see some green again on Friday or next week.
GLTA
A lot of us trade RG*B, but ENZC isn't related.
That's one scenario! Another possibility is that the Delaware Court of Chancery doesn't have jurisdiction in the case so there was no need for him to respond.
It will be a major step for him to start using any legal channels. He was acting outside the law contacting ENZC partners behind their backs.
Yours is definitely a more in-depth analysis than most of them!
Here's what I see:
Currently there are 2,797,935,953 outstanding shares. That makes the market cap $382,757,638 ($382 Million) at the current price of $.1368/share.
In a scenario where there are still 2,797,935,953 outstanding shares in 2026, but share price was $5, the market cap would be:
2,797,935,953 * $5/share = 13,989,679,765 or just about $14 Billion dollars.
If:
- ENZC can make 50% of the profit from Enzoimmune Active as revenue,
- The global immunomodulator market projections of $240 Billion collective worth by 2026 hold true,
- Rosetta can corner 1% of that market,
- No expensive lawsuits or other hurdles get in the way,
Then ENZC might be seeing a max of $240B * .01 * .50 = $1.2B in annual revenue (not including royalties) if I did the math right. Without further research, I'm not sure how this would factor into the share price, but it'd be decidedly higher than $0.13/share.
Now throw in Clone-3, any products from ENZC's conserved target sites patents, expansion into the veterinary industry... it starts to add up to some serious potential.
I can't speak for them, but I'm just a random anon fox on the internet.
Thanks for the heads up! If Savov isn't bluffing, it sounds like Savov is now threatening legal action against Harry. What a mess.
There is a valid point that Enzoimmune Active is supposed to have 20x lower toxicity than Tamiflu. The reference to Tamiflu actually comes from ENZC's own PR. Godfather did cite this source
$ENZC - 💥IMMUNOMODULATOR💥
— 𝐆𝐨𝐝𝐟𝐚𝐭𝐡𝐞𝐫 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 (@GodfatherCap) November 3, 2021
The Immunomodulator market is worth $240Billion (2026). EnzoImmune Active® addresses this market as its applicable to many diseases.
Tamiflu alone is worth $940MM, yet our product is more effective at a lower dosage and 20x less toxic!
READ 👇 https://t.co/K8LW4QRK7v pic.twitter.com/Ri5Yw8WlWO
I appreciate your attention to detail and I forgive you for earlier disrespect. There's a lot of frustration in these forums since everybody's in the red, and it's easy for everyone (me included) to vent our anger at one another. Iron sharpens iron, and there's a lot of good info to be gleaned from discussions like these. Thanks for your DD contributions and you have a great evening as well!
That's a good clarification, thanks. At one point I had wondered if IMPL/IMBL was a typo due to the unfortunate similarity of the abbreviations.
These are actually valuable points and the type of DD I encouraged you to share. So ima do a 180 and unblock ya.
But there's no good reason for you to use inflammatory and condescending language. It's dramatic and distracts everyone from the points you're trying to make.
From these filings:
https://www.otcmarkets.com/otcapi/company/financial-report/300160/content
https://www.otcmarkets.com/otcapi/company/financial-report/297979/content
ENZC lists the following as subsidiaries, affiliates and parent companies:
- Bioclonetics
- Biogenysis
- Virogentics
- ENZC SUB
- IMMB BG (49% owner)
- IMPL (50% owner? The OTC filings contradict by omission)
- Danhson Inc (contracted to produce the initial quantities of ITV-1 to be used for preclinical and clinical trial purposes)
There's one company not so clearly identified, but the description might match Rosetta:
So, yes GF's tweet about Rosetta Lifecare BG's EnzoImmune Active trademarking developments is related to ENZC, and yes you're nit-picking semantics. :P
(With the fair point that Rosetta Lifecare BG is listed on the trademark, not ENZC.)
Unfortunately, I'm blocking you now because you refuse to communicate constructively. GLTY
Noted, regarding the important minor details. And yes there's a big difference between an ENZC application and a Rosetta Lifecare BG application for EnzoImmune Active...
Did some more digging:
Thanks! I want this company to succeed as much as the rest of us. If these products work and were on the market already, they could potentially help save the lives of sick people who are very important to me. That alone is worth more than all the money I'd make on the stock.
Doing my best to keep up with investment news, in the midst of work and life. I definitely miss DD sometimes and it's good to get corrected on here when I say something off-track. :)
GLTY
Other than not realizing they'd already applied for trademark, what I posted originally wasn't false or misleading. I won't fight with you here; the newest post stands on its own with proper DD and links.
Didn't know that! :) Here's something for you:
There are trademark applications for EnzoImmune Active in a bunch of countries now, most dated 6/8. It appears all are pending except the ones for "EM" which is European Union.
From https://www3.wipo.int/branddb/en/
For the US trademark, according to https://www.uspto.gov/trademarks/basics/how-long-does-it-take-register
That's what I'm seeing too, yeah. This is not evidence of an application, surprised (and not surprised) GF is making that leap.
I'm not sure if power of attorney or trademark application comes first. My guess is get the legal side sorted first, then apply for trademark, then start using the branding after approval. Taking the legal step now (24 Oct per the date) suggests ENZC is getting ready to do work involving that EnzoImmune trademark in the top left corner of the letter.
Another GF tweet says it'll take 1-2 Months for a trademark application to get approved. So assuming no delays and that a trademark application was filed on Oct 24th right after the attorney letter was signed, it could be Thanksgiving or Christmas before there's trademark approval, and probably into January before the earliest possibility of product launch?
Another GF tweet points out that "Tamiflu alone is worth $940MM, yet our product is more effective at a lower dosage and 20x less toxic!" and if this spray has anti-covid properties, it'll probably sell pretty well.
https://stocktwits.com/GodfatherCap/message/400400296
Awesome post, thanks!
Enjoy the mountains, I was there last week and I want to go back. <3
Loving the look of this chart setup. :)
Warning: this post contains charts. Skip it if you don't believe in charting the OTC. (You'd think the disclaimer wouldn't be necessary but yeah...)
Tricky to illustrate, but we're looking at a possible inverse head & shoulders pattern as part of a much bigger inverse head & shoulders. The rules for these patterns say profit targets should be .06 and .10 respectively. (I put boxes around them on the first chart. They're visible both in daily candles and RSI.)
https://www.investopedia.com/terms/i/inverseheadandshoulders.asp
And what's also significant about .10? That's the profit target for the falling wedge as well!
https://www.investopedia.com/terms/w/wedge.asp
GLTA
Afaik Enzoimmune Active (ITV-1 which uses IPF) binds to the covid spike protein and blocks viral infection. It's a preventative but possibly a highly effective one. Clone 3 (monoclonal antibodies) bind to the gp41 target site on covid (the 'core' part of the virus) and possibly also to the spike protein just like IPF, blocking viral infection and acting more as a permanent "cure"
More about IPF on page 21
https://sec.report/otc/financial-report/123399
Both products increase white blood cell count and mutate white blood cells to be resistant to HIV and covid. Sounds good on paper, though it's monkeying with the body's natural immune function, so like mRNA there's some longer term question marks relating to unintended side effects. Will seem "safer" than mRNA gene therapy to some people. Effective HIV and covid treatments of any type are in great demand.
Yeah, I think it's a real product! Hopefully they have their supply lines, manufacturing process & scalability, web portal, pharmacy phone support, legal and regulatory worked out too. I don't doubt they've considered all this, but it's a lot to prepare & maintain with some possible growing pains along the way.
It's a bold claim. It'll do some real damage unless ENZC can deliver! But, if they can deliver, it'd be a huge step forward & finally a source of revenue.
What was once unimaginable at Enzolytics we are transforming into reality. We have only touched the tip of the iceberg thus far. Expect great things... #ENZCSTRONG #ENZC
— Gaurav Chandra M.D. (@drgauravchandra) November 3, 2021
Red day, but it found support where it needed to if it's gonna continue the run.
WARNING: Charts below, skip 'em if you don't believe in charting. ;)
I think TA is an important part of staying informed, investing on emotions alone is gambling.
Dashed lines are bollinger bands. Daily candle crossed over the midline and survived bears trying to pull it back under. It's also trading above the 200 day moving average (dark blue line) which is bullish. MACD (12,26) crossed already and is showing green ticks. The real fun will start if MACD (24,52) crosses in the next week or so.
https://www.investopedia.com/terms/m/macd.asp
https://www.investopedia.com/terms/b/bollingerbands.asp
Second chart is Fibonacci retracements on the 30 min. From the point of breakout, price found support around 61.8% which is the perfect place to finish consolidating for another run. Tomorrow has a lot of potential to be a green day. But without a news catalyst this is all still potentially a dead cat bounce, so be careful taking higher entries to avoid being a bagholder.
https://www.investopedia.com/terms/f/fibonacciretracement.asp
https://www.investopedia.com/articles/00/101700.asp
GLTA
That's an elaborate way to disagree. TA suits me better than 'to the moooon' and 'somebody must know something'. Make your best moves on your best info.
GLTA
Nothing too exciting on the charts, but I don't see any warning signs either. Tired fox today so I'll do minimal commentary.
The most interesting thing is the hourly chart, where the double-term MACD (at the very bottom of the image) is nearing a reflection or crossover. The half and full term MACDs are already crossed over and making green ticks. RSI is finally back up after an extended period of breakdowns. There was a recent bollinger crossover into the high band (dashed lines) which signals loss of bearish momentum. Price is just below bollinger midline so this is either going to retest the top band and hopefully break higher, or cross back over to the low band in a sideways channel.
Current prices should be strong support and I think price already made its new low yesterday. Could go to .116 briefly but I wouldn't gamble on it if you're looking to enter. Adding now / buying the breakout appears to be low-risk, but there's no excitement yet because news flow evaporated, so if you're not flipping brace for a long hold.
HOURLY chart:
DAILY chart:
Somebody played this just before lunch with some big buys and started the price moving. The MM rides the momentum and sells for modest gains, then backs off while retail mounts another rally. Then they sell the rest at the next peak and retail panic sells when there are no buyers.
This is under VWAP (the pink moving average) but above .021 which is the 90 day high volume price. So it's technically in bull territory and the market could pile on at tomorrow's open, reject the dump and really send this flying. But without a known catalyst it looks to be a quick pump play.
News always trumps charts. You may be right that there's something catalyzing in the pipeline. RGBP retested its April high on rumors of news.
I think you're missing the point. The shares are hot potatoes at the higher price, people weren't willing to buy or hold there. So where does price go?